holx-20230401false2023Q200008597379-28P3MP1YP1YP1YP1Y00008597372022-09-252023-04-0100008597372023-04-25xbrli:shares00008597372023-01-012023-04-01iso4217:USD00008597372021-12-262022-03-2600008597372021-09-262022-03-26iso4217:USDxbrli:shares00008597372023-04-0100008597372022-09-240000859737us-gaap:CommonStockMember2021-09-250000859737us-gaap:AdditionalPaidInCapitalMember2021-09-250000859737us-gaap:RetainedEarningsMember2021-09-250000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-250000859737us-gaap:TreasuryStockMember2021-09-2500008597372021-09-250000859737us-gaap:CommonStockMember2021-09-262021-12-250000859737us-gaap:AdditionalPaidInCapitalMember2021-09-262021-12-2500008597372021-09-262021-12-250000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-262021-12-250000859737us-gaap:TreasuryStockMember2021-09-262021-12-250000859737us-gaap:CommonStockMember2021-12-250000859737us-gaap:AdditionalPaidInCapitalMember2021-12-250000859737us-gaap:RetainedEarningsMember2021-12-250000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-250000859737us-gaap:TreasuryStockMember2021-12-2500008597372021-12-250000859737us-gaap:CommonStockMember2021-12-262022-03-260000859737us-gaap:AdditionalPaidInCapitalMember2021-12-262022-03-260000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-262022-03-260000859737us-gaap:TreasuryStockMember2021-12-262022-03-260000859737us-gaap:CommonStockMember2022-03-260000859737us-gaap:AdditionalPaidInCapitalMember2022-03-260000859737us-gaap:RetainedEarningsMember2022-03-260000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-260000859737us-gaap:TreasuryStockMember2022-03-2600008597372022-03-260000859737us-gaap:CommonStockMember2022-03-272022-06-250000859737us-gaap:AdditionalPaidInCapitalMember2022-03-272022-06-2500008597372022-03-272022-06-250000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-272022-06-250000859737us-gaap:CommonStockMember2022-06-250000859737us-gaap:AdditionalPaidInCapitalMember2022-06-250000859737us-gaap:RetainedEarningsMember2022-06-250000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-250000859737us-gaap:TreasuryStockMember2022-06-2500008597372022-06-250000859737us-gaap:CommonStockMember2022-06-262022-09-240000859737us-gaap:AdditionalPaidInCapitalMember2022-06-262022-09-2400008597372022-06-262022-09-240000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-262022-09-240000859737us-gaap:TreasuryStockMember2022-06-262022-09-240000859737us-gaap:CommonStockMember2022-09-240000859737us-gaap:AdditionalPaidInCapitalMember2022-09-240000859737us-gaap:RetainedEarningsMember2022-09-240000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-240000859737us-gaap:TreasuryStockMember2022-09-240000859737us-gaap:CommonStockMember2022-09-252022-12-310000859737us-gaap:AdditionalPaidInCapitalMember2022-09-252022-12-3100008597372022-09-252022-12-310000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-252022-12-310000859737us-gaap:TreasuryStockMember2022-09-252022-12-310000859737us-gaap:CommonStockMember2022-12-310000859737us-gaap:AdditionalPaidInCapitalMember2022-12-310000859737us-gaap:RetainedEarningsMember2022-12-310000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000859737us-gaap:TreasuryStockMember2022-12-3100008597372022-12-310000859737us-gaap:CommonStockMember2023-01-012023-04-010000859737us-gaap:AdditionalPaidInCapitalMember2023-01-012023-04-010000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-04-010000859737us-gaap:TreasuryStockMember2023-01-012023-04-010000859737us-gaap:CommonStockMember2023-04-010000859737us-gaap:AdditionalPaidInCapitalMember2023-04-010000859737us-gaap:RetainedEarningsMember2023-04-010000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-010000859737us-gaap:TreasuryStockMember2023-04-010000859737holx:CytologyPerinatalMembercountry:USholx:DiagnosticsMember2023-01-012023-04-010000859737holx:InternationalMemberholx:CytologyPerinatalMemberholx:DiagnosticsMember2023-01-012023-04-010000859737holx:CytologyPerinatalMemberholx:DiagnosticsMember2023-01-012023-04-010000859737holx:CytologyPerinatalMembercountry:USholx:DiagnosticsMember2021-12-262022-03-260000859737holx:InternationalMemberholx:CytologyPerinatalMemberholx:DiagnosticsMember2021-12-262022-03-260000859737holx:CytologyPerinatalMemberholx:DiagnosticsMember2021-12-262022-03-260000859737holx:MolecularDiagnosticsMembercountry:USholx:DiagnosticsMember2023-01-012023-04-010000859737holx:InternationalMemberholx:MolecularDiagnosticsMemberholx:DiagnosticsMember2023-01-012023-04-010000859737holx:MolecularDiagnosticsMemberholx:DiagnosticsMember2023-01-012023-04-010000859737holx:MolecularDiagnosticsMembercountry:USholx:DiagnosticsMember2021-12-262022-03-260000859737holx:InternationalMemberholx:MolecularDiagnosticsMemberholx:DiagnosticsMember2021-12-262022-03-260000859737holx:MolecularDiagnosticsMemberholx:DiagnosticsMember2021-12-262022-03-260000859737holx:BloodScreeningMembercountry:USholx:DiagnosticsMember2023-01-012023-04-010000859737holx:InternationalMemberholx:BloodScreeningMemberholx:DiagnosticsMember2023-01-012023-04-010000859737holx:BloodScreeningMemberholx:DiagnosticsMember2023-01-012023-04-010000859737holx:BloodScreeningMembercountry:USholx:DiagnosticsMember2021-12-262022-03-260000859737holx:InternationalMemberholx:BloodScreeningMemberholx:DiagnosticsMember2021-12-262022-03-260000859737holx:BloodScreeningMemberholx:DiagnosticsMember2021-12-262022-03-260000859737country:USholx:DiagnosticsMember2023-01-012023-04-010000859737holx:InternationalMemberholx:DiagnosticsMember2023-01-012023-04-010000859737holx:DiagnosticsMember2023-01-012023-04-010000859737country:USholx:DiagnosticsMember2021-12-262022-03-260000859737holx:InternationalMemberholx:DiagnosticsMember2021-12-262022-03-260000859737holx:DiagnosticsMember2021-12-262022-03-260000859737holx:BreastHealthMembercountry:USholx:BreastImagingMember2023-01-012023-04-010000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2023-01-012023-04-010000859737holx:BreastHealthMemberholx:BreastImagingMember2023-01-012023-04-010000859737holx:BreastHealthMembercountry:USholx:BreastImagingMember2021-12-262022-03-260000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2021-12-262022-03-260000859737holx:BreastHealthMemberholx:BreastImagingMember2021-12-262022-03-260000859737holx:BreastHealthMembercountry:USholx:InterventionalBreastSolutionsMember2023-01-012023-04-010000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2023-01-012023-04-010000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2023-01-012023-04-010000859737holx:BreastHealthMembercountry:USholx:InterventionalBreastSolutionsMember2021-12-262022-03-260000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2021-12-262022-03-260000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2021-12-262022-03-260000859737holx:BreastHealthMembercountry:US2023-01-012023-04-010000859737holx:BreastHealthMemberholx:InternationalMember2023-01-012023-04-010000859737holx:BreastHealthMember2023-01-012023-04-010000859737holx:BreastHealthMembercountry:US2021-12-262022-03-260000859737holx:BreastHealthMemberholx:InternationalMember2021-12-262022-03-260000859737holx:BreastHealthMember2021-12-262022-03-260000859737holx:GynSurgicalMembercountry:US2023-01-012023-04-010000859737holx:InternationalMemberholx:GynSurgicalMember2023-01-012023-04-010000859737holx:GynSurgicalMember2023-01-012023-04-010000859737holx:GynSurgicalMembercountry:US2021-12-262022-03-260000859737holx:InternationalMemberholx:GynSurgicalMember2021-12-262022-03-260000859737holx:GynSurgicalMember2021-12-262022-03-260000859737holx:SkeletalHealthMembercountry:US2023-01-012023-04-010000859737holx:InternationalMemberholx:SkeletalHealthMember2023-01-012023-04-010000859737holx:SkeletalHealthMember2023-01-012023-04-010000859737holx:SkeletalHealthMembercountry:US2021-12-262022-03-260000859737holx:InternationalMemberholx:SkeletalHealthMember2021-12-262022-03-260000859737holx:SkeletalHealthMember2021-12-262022-03-260000859737country:US2023-01-012023-04-010000859737holx:InternationalMember2023-01-012023-04-010000859737country:US2021-12-262022-03-260000859737holx:InternationalMember2021-12-262022-03-260000859737holx:CytologyPerinatalMembercountry:USholx:DiagnosticsMember2022-09-252023-04-010000859737holx:InternationalMemberholx:CytologyPerinatalMemberholx:DiagnosticsMember2022-09-252023-04-010000859737holx:CytologyPerinatalMemberholx:DiagnosticsMember2022-09-252023-04-010000859737holx:CytologyPerinatalMembercountry:USholx:DiagnosticsMember2021-09-262022-03-260000859737holx:InternationalMemberholx:CytologyPerinatalMemberholx:DiagnosticsMember2021-09-262022-03-260000859737holx:CytologyPerinatalMemberholx:DiagnosticsMember2021-09-262022-03-260000859737holx:MolecularDiagnosticsMembercountry:USholx:DiagnosticsMember2022-09-252023-04-010000859737holx:InternationalMemberholx:MolecularDiagnosticsMemberholx:DiagnosticsMember2022-09-252023-04-010000859737holx:MolecularDiagnosticsMemberholx:DiagnosticsMember2022-09-252023-04-010000859737holx:MolecularDiagnosticsMembercountry:USholx:DiagnosticsMember2021-09-262022-03-260000859737holx:InternationalMemberholx:MolecularDiagnosticsMemberholx:DiagnosticsMember2021-09-262022-03-260000859737holx:MolecularDiagnosticsMemberholx:DiagnosticsMember2021-09-262022-03-260000859737holx:BloodScreeningMembercountry:USholx:DiagnosticsMember2022-09-252023-04-010000859737holx:InternationalMemberholx:BloodScreeningMemberholx:DiagnosticsMember2022-09-252023-04-010000859737holx:BloodScreeningMemberholx:DiagnosticsMember2022-09-252023-04-010000859737holx:BloodScreeningMembercountry:USholx:DiagnosticsMember2021-09-262022-03-260000859737holx:InternationalMemberholx:BloodScreeningMemberholx:DiagnosticsMember2021-09-262022-03-260000859737holx:BloodScreeningMemberholx:DiagnosticsMember2021-09-262022-03-260000859737country:USholx:DiagnosticsMember2022-09-252023-04-010000859737holx:InternationalMemberholx:DiagnosticsMember2022-09-252023-04-010000859737holx:DiagnosticsMember2022-09-252023-04-010000859737country:USholx:DiagnosticsMember2021-09-262022-03-260000859737holx:InternationalMemberholx:DiagnosticsMember2021-09-262022-03-260000859737holx:DiagnosticsMember2021-09-262022-03-260000859737holx:BreastHealthMembercountry:USholx:BreastImagingMember2022-09-252023-04-010000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2022-09-252023-04-010000859737holx:BreastHealthMemberholx:BreastImagingMember2022-09-252023-04-010000859737holx:BreastHealthMembercountry:USholx:BreastImagingMember2021-09-262022-03-260000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2021-09-262022-03-260000859737holx:BreastHealthMemberholx:BreastImagingMember2021-09-262022-03-260000859737holx:BreastHealthMembercountry:USholx:InterventionalBreastSolutionsMember2022-09-252023-04-010000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2022-09-252023-04-010000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2022-09-252023-04-010000859737holx:BreastHealthMembercountry:USholx:InterventionalBreastSolutionsMember2021-09-262022-03-260000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2021-09-262022-03-260000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2021-09-262022-03-260000859737holx:BreastHealthMembercountry:US2022-09-252023-04-010000859737holx:BreastHealthMemberholx:InternationalMember2022-09-252023-04-010000859737holx:BreastHealthMember2022-09-252023-04-010000859737holx:BreastHealthMembercountry:US2021-09-262022-03-260000859737holx:BreastHealthMemberholx:InternationalMember2021-09-262022-03-260000859737holx:BreastHealthMember2021-09-262022-03-260000859737holx:GynSurgicalMembercountry:US2022-09-252023-04-010000859737holx:InternationalMemberholx:GynSurgicalMember2022-09-252023-04-010000859737holx:GynSurgicalMember2022-09-252023-04-010000859737holx:GynSurgicalMembercountry:US2021-09-262022-03-260000859737holx:InternationalMemberholx:GynSurgicalMember2021-09-262022-03-260000859737holx:GynSurgicalMember2021-09-262022-03-260000859737holx:SkeletalHealthMembercountry:US2022-09-252023-04-010000859737holx:InternationalMemberholx:SkeletalHealthMember2022-09-252023-04-010000859737holx:SkeletalHealthMember2022-09-252023-04-010000859737holx:SkeletalHealthMembercountry:US2021-09-262022-03-260000859737holx:InternationalMemberholx:SkeletalHealthMember2021-09-262022-03-260000859737holx:SkeletalHealthMember2021-09-262022-03-260000859737country:US2022-09-252023-04-010000859737holx:InternationalMember2022-09-252023-04-010000859737country:US2021-09-262022-03-260000859737holx:InternationalMember2021-09-262022-03-260000859737srt:EuropeMember2023-01-012023-04-010000859737srt:EuropeMember2021-12-262022-03-260000859737srt:EuropeMember2022-09-252023-04-010000859737srt:EuropeMember2021-09-262022-03-260000859737srt:AsiaPacificMember2023-01-012023-04-010000859737srt:AsiaPacificMember2021-12-262022-03-260000859737srt:AsiaPacificMember2022-09-252023-04-010000859737srt:AsiaPacificMember2021-09-262022-03-260000859737holx:RestofWorldMember2023-01-012023-04-010000859737holx:RestofWorldMember2021-12-262022-03-260000859737holx:RestofWorldMember2022-09-252023-04-010000859737holx:RestofWorldMember2021-09-262022-03-260000859737holx:ConsumablesMember2023-01-012023-04-010000859737holx:ConsumablesMember2021-12-262022-03-260000859737holx:ConsumablesMember2022-09-252023-04-010000859737holx:ConsumablesMember2021-09-262022-03-260000859737holx:CapitalEquipmentComponentsandSoftwareMember2023-01-012023-04-010000859737holx:CapitalEquipmentComponentsandSoftwareMember2021-12-262022-03-260000859737holx:CapitalEquipmentComponentsandSoftwareMember2022-09-252023-04-010000859737holx:CapitalEquipmentComponentsandSoftwareMember2021-09-262022-03-260000859737us-gaap:ServiceMember2023-01-012023-04-010000859737us-gaap:ServiceMember2021-12-262022-03-260000859737us-gaap:ServiceMember2022-09-252023-04-010000859737us-gaap:ServiceMember2021-09-262022-03-260000859737holx:OtherTypeofRevenueMember2023-01-012023-04-010000859737holx:OtherTypeofRevenueMember2021-12-262022-03-260000859737holx:OtherTypeofRevenueMember2022-09-252023-04-010000859737holx:OtherTypeofRevenueMember2021-09-262022-03-2600008597372023-03-292023-04-01xbrli:pure00008597372024-03-292023-04-0100008597372025-03-292023-04-0100008597372026-03-292023-04-0100008597372027-03-292023-04-010000859737us-gaap:InterestRateSwapMember2023-04-010000859737us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMember2023-04-010000859737us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2023-04-010000859737us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMember2023-04-010000859737us-gaap:ForeignExchangeContractMember2023-04-010000859737us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-04-010000859737us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member2023-04-010000859737us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2023-04-010000859737us-gaap:ForeignExchangeOptionMember2023-04-010000859737us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeOptionMember2023-04-010000859737us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeOptionMember2023-04-010000859737us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeOptionMember2023-04-010000859737us-gaap:FairValueInputsLevel1Member2023-04-010000859737us-gaap:FairValueInputsLevel2Member2023-04-010000859737us-gaap:FairValueInputsLevel3Member2023-04-010000859737holx:ContingentConsiderationMember2023-04-010000859737holx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2023-04-010000859737holx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel2Member2023-04-010000859737holx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-04-010000859737us-gaap:EquityMethodInvestmentsMember2021-12-262022-03-260000859737holx:CreditAgreementMember2023-04-010000859737us-gaap:SeniorNotesMemberholx:A2028SeniorNotesMember2023-04-010000859737us-gaap:SeniorNotesMemberholx:A2029SeniorNotesMember2023-04-010000859737holx:A2028SeniorNotesMember2023-04-010000859737holx:A2029SeniorNotesMember2023-04-010000859737holx:BolderSurgicalMember2021-11-292021-11-290000859737holx:BolderSurgicalMember2021-11-290000859737holx:DevelopedTechnologyMemberholx:BolderSurgicalMember2021-11-292021-11-290000859737us-gaap:TradeNamesMemberholx:BolderSurgicalMember2021-11-292021-11-290000859737us-gaap:CustomerRelationshipsMemberholx:BolderSurgicalMember2021-11-292021-11-290000859737holx:AcessaHealthMember2020-08-230000859737holx:AcessaHealthMember2020-08-232020-08-230000859737holx:AcessaHealthMember2021-09-262022-09-240000859737holx:AcessaHealthMember2021-09-262021-12-250000859737holx:AcessaHealthMember2021-12-262022-03-260000859737holx:AcessaHealthMember2023-01-012023-04-010000859737holx:AcessaHealthMember2023-04-010000859737holx:DanburyClosureMember2023-01-012023-04-010000859737holx:DanburyClosureMember2022-09-252023-04-010000859737holx:DanburyClosureMember2021-09-262022-03-260000859737holx:DanburyClosureMember2023-04-010000859737holx:GermanyPlanMember2023-01-012023-04-010000859737holx:GermanyPlanMember2022-09-252023-04-010000859737holx:GermanyPlanMember2023-04-010000859737holx:TermLoanMember2023-04-010000859737holx:TermLoanMember2022-09-240000859737holx:A2028SeniorNotesMember2023-04-010000859737holx:A2028SeniorNotesMember2022-09-240000859737holx:A2029SeniorNotesMember2023-04-010000859737holx:A2029SeniorNotesMember2022-09-240000859737holx:SecuredTermLoanMemberholx:A2021TermLoanMember2021-09-270000859737holx:RevolverMemberholx:A2021RevolverMember2021-09-270000859737holx:SecuredTermLoanMemberholx:A2021TermLoanMember2023-04-010000859737holx:A2021CreditAgreementMemberholx:TermLoanMember2023-01-012023-04-010000859737holx:A2021CreditAgreementMemberholx:TermLoanMember2023-04-010000859737holx:CreditAgreementMember2023-01-012023-04-010000859737holx:CreditAgreementMember2021-12-262022-03-260000859737holx:CreditAgreementMember2022-09-252023-04-010000859737holx:CreditAgreementMember2021-09-262022-03-260000859737holx:CreditAgreementMember2022-03-260000859737us-gaap:InterestRateSwapMember2023-04-010000859737us-gaap:InterestRateSwapMember2023-01-012023-04-010000859737us-gaap:InterestRateSwapMember2022-09-252023-04-010000859737us-gaap:SeniorNotesMemberholx:A2028SeniorNotesMember2023-01-012023-04-010000859737us-gaap:SeniorNotesMemberholx:A2028SeniorNotesMember2021-12-262022-03-260000859737us-gaap:SeniorNotesMemberholx:A2028SeniorNotesMember2022-09-252023-04-010000859737us-gaap:SeniorNotesMemberholx:A2028SeniorNotesMember2021-09-262022-03-260000859737us-gaap:SeniorNotesMemberholx:A2029SeniorNotesMember2023-01-012023-04-010000859737us-gaap:SeniorNotesMemberholx:A2029SeniorNotesMember2021-12-262022-03-260000859737us-gaap:SeniorNotesMemberholx:A2029SeniorNotesMember2022-09-252023-04-010000859737us-gaap:SeniorNotesMemberholx:A2029SeniorNotesMember2021-09-262022-03-260000859737us-gaap:SeniorNotesMemberholx:A2028And2029SeniorNotesMember2023-01-012023-04-010000859737us-gaap:SeniorNotesMemberholx:A2028And2029SeniorNotesMember2021-12-262022-03-260000859737us-gaap:SeniorNotesMemberholx:A2028And2029SeniorNotesMember2022-09-252023-04-010000859737us-gaap:SeniorNotesMemberholx:A2028And2029SeniorNotesMember2021-09-262022-03-260000859737holx:AssetSecuritizationMember2022-04-012022-04-300000859737us-gaap:InterestRateSwapMember2022-09-240000859737holx:InterestRateSwap2024Member2023-03-230000859737holx:InterestRateSwap2023Member2023-03-230000859737holx:InterestRateSwap2023Member2023-04-010000859737holx:InterestRateSwap2024Member2023-04-010000859737us-gaap:ForwardContractsMember2023-04-010000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-04-010000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-12-262022-03-260000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-09-252023-04-010000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-09-262022-03-260000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2023-01-012023-04-010000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2021-12-262022-03-260000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2022-09-252023-04-010000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2021-09-262022-03-260000859737us-gaap:NondesignatedMember2023-01-012023-04-010000859737us-gaap:NondesignatedMember2021-12-262022-03-260000859737us-gaap:NondesignatedMember2022-09-252023-04-010000859737us-gaap:NondesignatedMember2021-09-262022-03-260000859737us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-04-010000859737us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-09-240000859737us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherCurrentAssetsMember2023-04-010000859737us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherCurrentAssetsMember2022-09-240000859737us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-04-010000859737us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-09-240000859737us-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2023-04-010000859737us-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2022-09-240000859737us-gaap:ForeignExchangeOptionMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2023-04-010000859737us-gaap:ForeignExchangeOptionMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2022-09-240000859737us-gaap:NondesignatedMember2023-04-010000859737us-gaap:NondesignatedMember2022-09-240000859737us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:NondesignatedMember2023-04-010000859737us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:NondesignatedMember2022-09-240000859737us-gaap:ForeignExchangeForwardMemberus-gaap:AccruedLiabilitiesMemberus-gaap:NondesignatedMember2023-04-010000859737us-gaap:ForeignExchangeForwardMemberus-gaap:AccruedLiabilitiesMemberus-gaap:NondesignatedMember2022-09-240000859737us-gaap:InterestRateSwapMember2021-12-262022-03-260000859737us-gaap:InterestRateSwapMember2021-09-262022-03-260000859737holx:MinervaMember2018-07-270000859737holx:MinervaMember2016-03-042016-03-04holx:petition0000859737holx:MinervaMember2023-01-012023-04-010000859737us-gaap:StockCompensationPlanMember2023-01-012023-04-010000859737us-gaap:StockCompensationPlanMember2021-12-262022-03-260000859737us-gaap:StockCompensationPlanMember2022-09-252023-04-010000859737us-gaap:StockCompensationPlanMember2021-09-262022-03-260000859737us-gaap:CostOfSalesMember2023-01-012023-04-010000859737us-gaap:CostOfSalesMember2021-12-262022-03-260000859737us-gaap:CostOfSalesMember2022-09-252023-04-010000859737us-gaap:CostOfSalesMember2021-09-262022-03-260000859737us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-04-010000859737us-gaap:ResearchAndDevelopmentExpenseMember2021-12-262022-03-260000859737us-gaap:ResearchAndDevelopmentExpenseMember2022-09-252023-04-010000859737us-gaap:ResearchAndDevelopmentExpenseMember2021-09-262022-03-260000859737us-gaap:SellingAndMarketingExpenseMember2023-01-012023-04-010000859737us-gaap:SellingAndMarketingExpenseMember2021-12-262022-03-260000859737us-gaap:SellingAndMarketingExpenseMember2022-09-252023-04-010000859737us-gaap:SellingAndMarketingExpenseMember2021-09-262022-03-260000859737us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-04-010000859737us-gaap:GeneralAndAdministrativeExpenseMember2021-12-262022-03-260000859737us-gaap:GeneralAndAdministrativeExpenseMember2022-09-252023-04-010000859737us-gaap:GeneralAndAdministrativeExpenseMember2021-09-262022-03-260000859737us-gaap:EmployeeStockOptionMember2022-09-252023-04-010000859737us-gaap:EmployeeStockOptionMember2021-09-262022-03-260000859737us-gaap:EmployeeStockOptionMember2023-04-010000859737us-gaap:RestrictedStockUnitsRSUMember2022-09-252023-04-010000859737us-gaap:RestrictedStockUnitsRSUMember2021-09-262022-03-260000859737us-gaap:PerformanceSharesMember2022-09-252023-04-010000859737us-gaap:PerformanceSharesMember2021-09-262022-03-260000859737holx:MarketBasedAwardsMember2022-09-252023-04-010000859737holx:PSUFreeCashFlowMember2022-09-252023-04-010000859737holx:PSUFreeCashFlowMember2021-09-262022-03-260000859737holx:MarketBasedAwardsMember2021-09-262022-03-260000859737holx:RSUPSUMSUMember2023-04-010000859737us-gaap:RestrictedStockUnitsRSUMember2023-04-0100008597372020-06-282020-09-2600008597372020-09-272020-12-26holx:Segment0000859737us-gaap:IntersegmentEliminationMember2023-01-012023-04-010000859737us-gaap:IntersegmentEliminationMember2021-12-262022-03-260000859737us-gaap:IntersegmentEliminationMember2021-09-262022-03-260000859737us-gaap:IntersegmentEliminationMember2022-09-252023-04-010000859737us-gaap:CorporateMember2023-01-012023-04-010000859737us-gaap:CorporateMember2021-12-262022-03-260000859737us-gaap:CorporateMember2022-09-252023-04-010000859737us-gaap:CorporateMember2021-09-262022-03-260000859737holx:DiagnosticsMember2023-04-010000859737holx:DiagnosticsMember2022-09-240000859737holx:BreastHealthMember2023-04-010000859737holx:BreastHealthMember2022-09-240000859737holx:GynSurgicalMember2023-04-010000859737holx:GynSurgicalMember2022-09-240000859737holx:SkeletalHealthMember2023-04-010000859737holx:SkeletalHealthMember2022-09-240000859737us-gaap:CorporateMember2023-04-010000859737us-gaap:CorporateMember2022-09-240000859737holx:AllOtherCountriesMember2023-01-012023-04-010000859737holx:AllOtherCountriesMember2021-12-262022-03-260000859737holx:AllOtherCountriesMember2022-09-252023-04-010000859737holx:AllOtherCountriesMember2021-09-262022-03-260000859737holx:DevelopedTechnologyMember2023-04-010000859737holx:DevelopedTechnologyMember2022-09-240000859737us-gaap:InProcessResearchAndDevelopmentMember2023-04-010000859737us-gaap:InProcessResearchAndDevelopmentMember2022-09-240000859737holx:CustomerRelationshipsContractsMember2023-04-010000859737holx:CustomerRelationshipsContractsMember2022-09-240000859737us-gaap:TradeNamesMember2023-04-010000859737us-gaap:TradeNamesMember2022-09-240000859737holx:AcquiredintangibleassetsMember2023-04-010000859737holx:AcquiredintangibleassetsMember2022-09-240000859737holx:InternalusesoftwareMember2023-04-010000859737holx:InternalusesoftwareMember2022-09-240000859737holx:CapitalizedsoftwareMember2023-04-010000859737holx:CapitalizedsoftwareMember2022-09-240000859737us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000859737us-gaap:AccumulatedTranslationAdjustmentMember2022-09-240000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-240000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-240000859737us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-04-010000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-04-010000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-04-010000859737us-gaap:AccumulatedTranslationAdjustmentMember2022-09-252023-04-010000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-252023-04-010000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-252023-04-010000859737us-gaap:AccumulatedTranslationAdjustmentMember2023-04-010000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-010000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-010000859737us-gaap:AccumulatedTranslationAdjustmentMember2021-12-250000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-250000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-250000859737us-gaap:AccumulatedTranslationAdjustmentMember2021-09-250000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-250000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-250000859737us-gaap:AccumulatedTranslationAdjustmentMember2021-12-262022-03-260000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-262022-03-260000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-262022-03-260000859737us-gaap:AccumulatedTranslationAdjustmentMember2021-09-262022-03-260000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-262022-03-260000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-262022-03-260000859737us-gaap:AccumulatedTranslationAdjustmentMember2022-03-260000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-260000859737us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-260000859737holx:September222022Member2023-04-010000859737holx:December112020Member2023-04-010000859737holx:September222022Member2023-01-012023-04-010000859737holx:September222022Member2022-09-252023-04-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________
FORM 10-Q
__________________________________________________________
(Mark One)
| | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended April 1, 2023
or
| | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 1-36214
__________________________________________________________
HOLOGIC, INC.
(Exact name of registrant as specified in its charter)
__________________________________________________________
| | | | | | | | |
Delaware | | 04-2902449 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
250 Campus Drive, | | |
Marlborough, | | |
Massachusetts
| | 01752 |
(Address of principal executive offices) | | (Zip Code) |
(508) 263-2900
(Registrant’s telephone number, including area code)
__________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $0.01 par value | HOLX | NASDAQ |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | | | | |
Large accelerated filer | | ☒ | | Accelerated filer | | ☐ |
Non-accelerated filer | | ☐ | | Smaller reporting company | | ☐ |
| | | | Emerging growth company | | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of April 25, 2023, 246,118,192 shares of the registrant’s Common Stock, $0.01 par value, were outstanding.
HOLOGIC, INC.
INDEX
| | | | | | | | |
| Page |
| |
| |
| |
Item 1. | | |
| |
| | |
| |
| | |
| |
| | |
| |
| | |
| | |
| | |
| |
| | |
| |
Item 2. | | |
| |
Item 3. | | |
| |
Item 4. | | |
| |
| |
| | |
Item 1. | | |
| | |
Item 1A. | | |
| | |
Item 2. | | |
| | |
Item 6. | | |
| |
| |
| |
EXHIBITS | |
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and per share data)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended |
| April 1, 2023 | | March 26, 2022 | | April 1, 2023 | | March 26, 2022 |
Revenues: | | | | | | | |
Product | $ | 837.4 | | | $ | 1,268.2 | | | $ | 1,723.8 | | | $ | 2,571.6 | |
Service and other | 189.1 | | | 167.5 | | | 376.9 | | | 335.3 | |
| 1,026.5 | | | 1,435.7 | | | 2,100.7 | | | 2,906.9 | |
Costs of revenues: | | | | | | | |
Product | 292.1 | | | 322.6 | | | 588.3 | | | 640.7 | |
Amortization of acquired intangible assets | 52.1 | | | 72.3 | | | 107.7 | | | 147.2 | |
| | | | | | | |
Service and other | 96.5 | | | 94.2 | | | 201.0 | | | 186.1 | |
Gross profit | 585.8 | | | 946.6 | | | 1,203.7 | | | 1,932.9 | |
Operating expenses: | | | | | | | |
Research and development | 74.0 | | | 69.5 | | | 148.8 | | | 142.3 | |
Selling and marketing | 142.4 | | | 171.4 | | | 305.9 | | | 318.7 | |
General and administrative | 100.8 | | | 100.5 | | | 209.3 | | | 218.5 | |
Amortization of acquired intangible assets | 7.1 | | | 11.3 | | | 14.7 | | | 22.1 | |
| | | | | | | |
| | | | | | | |
Contingent consideration - fair value adjustments | (12.4) | | | — | | | (12.4) | | | (4.1) | |
| | | | | | | |
| | | | | | | |
Restructuring charges | 1.8 | | | (0.2) | | | 2.9 | | | — | |
| 313.7 | | | 352.5 | | | 669.2 | | | 697.5 | |
Income from operations | 272.1 | | | 594.1 | | | 534.5 | | | 1,235.4 | |
Interest income | 31.5 | | | 0.8 | | | 52.1 | | | 1.2 | |
Interest expense | (27.2) | | | (22.6) | | | (55.3) | | | (48.3) | |
Debt extinguishment loss | — | | | — | | | — | | | (0.7) | |
Other income (expense), net | 2.9 | | | 2.1 | | | (12.9) | | | 8.7 | |
Income before income taxes | 279.3 | | | 574.4 | | | 518.4 | | | 1,196.3 | |
Provision for income taxes | 60.8 | | | 118.7 | | | 112.5 | | | 241.4 | |
Net income | $ | 218.5 | | | $ | 455.7 | | | $ | 405.9 | | | $ | 954.9 | |
Net income per common share: | | | | | | | |
Basic | $ | 0.88 | | | $ | 1.81 | | | $ | 1.64 | | | $ | 3.78 | |
Diluted | $ | 0.87 | | | $ | 1.80 | | | $ | 1.63 | | | $ | 3.75 | |
Weighted average number of shares outstanding: | | | | | | | |
Basic | 247,730 | | | 251,574 | | | 247,524 | | | 252,537 | |
Diluted | 249,793 | | | 253,658 | | | 249,537 | | | 254,864 | |
See accompanying notes.
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended |
| April 1, 2023 | | March 26, 2022 | | April 1, 2023 | | March 26, 2022 |
Net income | $ | 218.5 | | | $ | 455.7 | | | $ | 405.9 | | | $ | 954.9 | |
Changes in foreign currency translation adjustment | 15.3 | | | (34.5) | | | 129.1 | | | (72.3) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Changes in value of hedged interest rate swaps, net of tax of $(2.0) and $(2.9) for the three and six months ended April 1, 2023 and $6.5 and $9.1 for the three and six months ended March 26, 2022. | | | | | | | |
Gain (loss) recognized in other comprehensive income (loss), net | (6.4) | | | 19.4 | | | (9.3) | | | 27.3 | |
| | | | | | | |
Other comprehensive income (loss) | 8.9 | | | (15.1) | | | 119.8 | | | (45.0) | |
Comprehensive income | $ | 227.4 | | | $ | 440.6 | | | $ | 525.7 | | | $ | 909.9 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
See accompanying notes.
HOLOGIC, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and par value)
| | | | | | | | | | | |
| April 1, 2023 | | September 24, 2022 |
ASSETS | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 2,582.2 | | | $ | 2,339.5 | |
| | | |
| | | |
Accounts receivable, less reserves | 714.0 | | | 617.6 | |
Inventories | 687.6 | | | 623.7 | |
Prepaid expenses and other current assets | 187.0 | | | 232.2 | |
Prepaid income taxes | 40.6 | | | 49.0 | |
| | | |
| | | |
Total current assets | 4,211.4 | | | 3,862.0 | |
Property, plant and equipment, net | 497.9 | | | 481.6 | |
Intangible assets, net | 1,202.2 | | | 1,280.6 | |
Goodwill | 3,296.9 | | | 3,236.5 | |
Other assets | 240.3 | | | 210.5 | |
Total assets | $ | 9,448.7 | | | $ | 9,071.2 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
Current liabilities: | | | |
Current portion of long-term debt | $ | 26.2 | | | $ | 15.0 | |
Accounts payable | 187.4 | | | 197.7 | |
Accrued expenses | 508.0 | | | 535.3 | |
Deferred revenue | 230.5 | | | 186.5 | |
Finance lease obligations | 2.9 | | | 3.2 | |
| | | |
| | | |
Total current liabilities | 955.0 | | | 937.7 | |
Long-term debt, net of current portion | 2,797.7 | | | 2,808.4 | |
Finance lease obligations, net of current portion | 17.0 | | | 18.0 | |
Deferred income tax liabilities | 33.4 | | | 90.8 | |
Deferred revenue, net of current portion | 12.8 | | | 9.4 | |
Other long-term liabilities | 332.0 | | | 330.7 | |
Stockholders’ equity: | | | |
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued | — | | | — | |
Common stock, $0.01 par value – 750,000 shares authorized; 299,676 and 298,533 shares issued, respectively | 3.0 | | | 3.0 | |
Additional paid-in-capital | 6,091.5 | | | 6,042.6 | |
Retained earnings | 2,006.2 | | | 1,600.3 | |
Treasury stock, at cost – 53,566 and 51,401 shares, respectively | (2,681.5) | | | (2,531.5) | |
Accumulated other comprehensive loss | (118.4) | | | (238.2) | |
Total stockholders’ equity | 5,300.8 | | | 4,876.2 | |
Total liabilities and stockholders’ equity | $ | 9,448.7 | | | $ | 9,071.2 | |
See accompanying notes.
Hologic, Inc.
Consolidated Statements of Stockholders’ Equity
(In millions, except number of shares, which are reflected in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Common Stock | | Additional Paid-in- Capital | | Retained Earnings | | Accumulated Other Comprehensive Loss | | Treasury Stock | | | | Total Stockholders’ Equity |
| | Number of Shares | | Par Value | | Number of Shares | | Amount | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
Balance at September 25, 2021 | | 297,306 | | | $ | 3.0 | | | $ | 5,965.8 | | | $ | 298.3 | | | $ | (59.1) | | | 43,653 | | | $ | (1,989.4) | | | | | $ | 4,218.6 | |
Exercise of stock options | | 45 | | | — | | | 1.9 | | | — | | | — | | | — | | | — | | | | | 1.9 | |
Vesting of restricted stock units, net | | 534 | | | — | | | (22.4) | | | — | | | — | | | — | | | — | | | | | (22.4) | |
| | | | | | | | | | | | | | | | | | |
Stock-based compensation | | — | | | — | | | 18.7 | | | — | | | — | | | — | | | — | | | | | 18.7 | |
Net income | | — | | | — | | | — | | | 499.2 | | | — | | | — | | | — | | | | | 499.2 | |
Other comprehensive income activity | | — | | | — | | | — | | | — | | | (29.9) | | | — | | | — | | | | | (29.9) | |
Repurchase of common stock | | — | | | — | | | — | | | — | | | — | | | 2,335 | | | (167.0) | | | | | (167.0) | |
Balance at December 25, 2021 | | 297,885 | | | $ | 3.0 | | | $ | 5,964.0 | | | $ | 797.5 | | | $ | (89.0) | | | 45,988 | | | $ | (2,156.4) | | | | | $ | 4,519.1 | |
Exercise of stock options | | 140 | | | — | | | 5.8 | | | — | | | — | | | — | | | — | | | | | 5.8 | |
Vesting of restricted stock units, net | | 14 | | | — | | | (0.1) | | | — | | | — | | | — | | | — | | | | | (0.1) | |
Common stock issued under the employee stock purchase plan | | 164 | | | — | | | 9.5 | | | — | | | — | | | — | | | — | | | | | 9.5 | |
Stock-based compensation | | — | | | — | | | 17.8 | | | — | | | — | | | — | | | — | | | | | 17.8 | |
Net income | | — | | | — | | | — | | | 455.7 | | | — | | | — | | | — | | | | | 455.7 | |
Other comprehensive income activity | | — | | | — | | | — | | | — | | | (15.1) | | | — | | | — | | | | | (15.1) | |
Repurchase of common stock | | — | | | — | | | — | | | — | | | — | | | 2,863 | | | (200.0) | | | | | (200.0) | |
Balance at March 26, 2022 | | 298,203 | | | $ | 3.0 | | | $ | 5,997.0 | | | $ | 1,253.2 | | | $ | (104.1) | | | 48,851 | | | $ | (2,356.4) | | | | | $ | 4,792.7 | |
Exercise of stock options | | 128 | | | — | | | 5.2 | | | — | | | — | | | — | | | — | | | | | 5.2 | |
Vesting of restricted stock units, net | | 4 | | | — | | | (0.1) | | | — | | | — | | | — | | | — | | | | | (0.1) | |
| | | | | | | | | | | | | | | | | | |
Stock-based compensation | | — | | | — | | | 15.3 | | | — | | | — | | | — | | | — | | | | | 15.3 | |
Net income | | — | | | — | | | — | | | 228.4 | | | — | | | — | | | — | | | | | 228.4 | |
Other comprehensive income activity | | — | | | — | | | — | | | — | | | (43.6) | | | — | | | — | | | | | (43.6) | |
| | | | | | | | | | | | | | | | | | |
Balance at June 25, 2022 | | 298,335 | | | $ | 3.0 | | | $ | 6,017.4 | | | $ | 1,481.6 | | | $ | (147.7) | | | 48,851 | | | $ | (2,356.4) | | | | | $ | 4,997.9 | |
Exercise of stock options | | 23 | | | — | | | 0.9 | | | — | | | — | | | — | | | — | | | | | 0.9 | |
Vesting of restricted stock units, net | | 9 | | | — | | | (0.3) | | | — | | | — | | | — | | | — | | | | | (0.3) | |
Common stock issued under the employee stock purchase plan | | 166 | | | — | | | 9.7 | | | — | | | — | | | — | | | — | | | | | 9.7 | |
Stock-based compensation | | — | | | — | | | 14.9 | | | — | | | — | | | — | | | — | | | | | 14.9 | |
Net income | | — | | | — | | | — | | | 118.7 | | | — | | | — | | | — | | | | | 118.7 | |
Other comprehensive income activity | | — | | | — | | | — | | | — | | | (90.5) | | | — | | | — | | | | | (90.5) | |
Repurchase of common stock | | — | | | — | | | — | | | — | | | — | | | 2,550 | | | $ | (175.1) | | | | | (175.1) | |
Balance at September 24, 2022 | | 298,533 | | | $ | 3.0 | | | $ | 6,042.6 | | | $ | 1,600.3 | | | $ | (238.2) | | | 51,401 | | | $ | (2,531.5) | | | | | $ | 4,876.2 | |
Exercise of stock options | | 267 | | | — | | | 10.3 | | | — | | | — | | | — | | | — | | | | | 10.3 | |
Vesting of restricted stock units, net | | 514 | | | — | | | (23.0) | | | — | | | — | | | — | | | — | | | | | (23.0) | |
Common stock issued under the employee stock purchase plan | | 171 | | | — | | | 10.2 | | | — | | | — | | | — | | | — | | | | | 10.2 | |
Stock-based compensation | | — | | | — | | | 20.5 | | | — | | | — | | | — | | | — | | | | | 20.5 | |
Net income | | — | | | — | | | — | | | 187.4 | | | — | | | — | | | — | | | | | 187.4 | |
Other comprehensive income activity | | — | | | — | | | — | | | — | | | 110.9 | | | — | | | — | | | | | 110.9 | |
Repurchase of common stock | | — | | | — | | | — | | | — | | | — | | | 1,539 | | | (100.0) | | | | | (100.0) | |
Balance at December 31, 2022 | | 299,485 | | | $ | 3.0 | | | $ | 6,060.6 | | | $ | 1,787.7 | | | $ | (127.3) | | | 52,940 | | | $ | (2,631.5) | | | | | $ | 5,092.5 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Exercise of stock options | | 173 | | | — | | | 7.9 | | | — | | | — | | | — | | | — | | | | | 7.9 | |
Vesting of restricted stock units, net | | 18 | | | — | | | (0.2) | | | — | | | — | | | — | | | — | | | | | (0.2) | |
| | | | | | | | | | | | | | | | | | |
Stock-based compensation | | — | | | — | | | 23.2 | | | — | | | — | | | — | | | — | | | | | 23.2 | |
Net income | | — | | | — | | | — | | | 218.5 | | | — | | | — | | | — | | | | | 218.5 | |
Other comprehensive income activity | | — | | | — | | | — | | | — | | | 8.9 | | | — | | | — | | | | | 8.9 | |
Repurchase of common stock | | — | | | — | | | — | | | — | | | — | | | 626 | | | (50.0) | | | | | (50.0) | |
Balance at April 1, 2023 | | 299,676 | | | $ | 3.0 | | | $ | 6,091.5 | | | $ | 2,006.2 | | | $ | (118.4) | | | 53,566 | | | $ | (2,681.5) | | | | | $ | 5,300.8 | |
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In millions)
| | | | | | | | | | | |
| Six Months Ended |
| April 1, 2023 | | March 26, 2022 |
OPERATING ACTIVITIES | | | |
Net income | $ | 405.9 | | | $ | 954.9 | |
Adjustments to reconcile net income to net cash provided by operating activities: | | | |
Depreciation | 44.3 | | | 44.9 | |
Amortization of acquired intangible assets | 122.4 | | | 169.2 | |
| | | |
Stock-based compensation expense | 43.7 | | | 36.5 | |
Deferred income taxes | (61.6) | | | (41.5) | |
| | | |
| | | |
| | | |
| | | |
| | | |
Contingent consideration - fair value adjustments | (12.4) | | | (4.1) | |
| | | |
| | | |
| | | |
| | | |
| | | |
Other adjustments and non-cash items | 29.6 | | | 23.5 | |
Changes in operating assets and liabilities, excluding the effect of acquisitions: | | | |
Accounts receivable | (81.8) | | | 101.6 | |
Inventories | (56.1) | | | (26.4) | |
Prepaid income taxes | 8.3 | | | (6.4) | |
Prepaid expenses and other assets | 10.5 | | | 355.3 | |
Accounts payable | (13.2) | | | 9.1 | |
Accrued expenses and other liabilities | (22.4) | | | 2.9 | |
Deferred revenue | 42.5 | | | 6.9 | |
Net cash provided by operating activities | 459.7 | | | 1,626.4 | |
INVESTING ACTIVITIES | | | |
Acquisition of business, net of cash acquired | — | | | (158.4) | |
| | | |
| | | |
Capital expenditures | (34.5) | | | (36.1) | |
Proceeds from the Department of Defense | 20.5 | | | 58.7 | |
Increase in equipment under customer usage agreements | (26.7) | | | (33.8) | |
| | | |
| | | |
| | | |
| | | |
| | | |
Purchase of equity investment | (10.0) | | | — | |
| | | |
| | | |
Other activity | (6.7) | | | 5.2 | |
| | | |
Net cash used in investing activities | (57.4) | | | (164.4) | |
FINANCING ACTIVITIES | | | |
Proceeds from long-term debt, net of issuance costs | — | | | 1,491.2 | |
Repayment of long-term debt | (7.5) | | | (1,387.5) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Payment of contingent consideration | (7.6) | | | (12.2) | |
| | | |
Payment of deferred acquisition consideration | (0.8) | | | — | |
Repayment of acquired long-term debt | — | | | (63.6) | |
| | | |
| | | |
Repurchases of common stock | (150.0) | | | (367.0) | |
| | | |
Proceeds from issuance of common stock pursuant to employee stock plans | 28.4 | | | 17.3 | |
Payment of minimum tax withholdings on net share settlements of equity awards | (23.2) | | | (22.5) | |
Payments under finance lease obligations | (2.3) | | | (1.7) | |
Net cash used in financing activities | (163.0) | | | (346.0) | |
Effect of exchange rate changes on cash and cash equivalents | 3.4 | | | 4.5 | |
Net increase in cash and cash equivalents | 242.7 | | | |